-
1 Comment
From a valuation standpoint, the stock is 20.5% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 1613.4.
Based on the above factors, Lucira Health, Inc. Common Stock gets an overall score of 0/5.
| ISIN | US54948U1051 |
|---|---|
| Sector | Healthcare |
| Industry | Healthcare Equipment & Supplies |
| Exchange | NASDAQ |
| CurrencyCode | USD |
| Market Cap | 18M |
|---|---|
| Beta | 3.76 |
| PE Ratio | None |
| Target Price | 0.5 |
| Dividend Yield | 0.0% |
Lucira Health, Inc., a medical technology company, focuses on the development and commercialization of infectious disease test kits. It develops a testing platform that produces molecular testing services. The company offers LUCIRA COVID-19 All-In-One Test Kit, a COVID-19 test kit; and develops influenza A and B viruses test kits. It has a patent license agreement with Eiken Chemical Co., Ltd.; technical services agreement with Jabil, Inc.; and manufacturing services agreement with Jabil MSA. The company was formerly known as DiAssess Inc. and changed its name to Lucira Health, Inc. in January 2020. Lucira Health, Inc. was incorporated in 2013 and is headquartered in Emeryville, California. On February 22, 2023, Lucira Health, Inc., filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for LHDX using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
